NHSA Seeks Public Input on National Reimbursement Drug List Adjustments
The National Healthcare Security Administration (NHSA) has unveiled the adjustment plan for the National Reimbursement...
Eli Lilly’s Baqsimi Gains NMPA Approval for Diabetes Hypoglycemia Treatment
The National Medical Products Administration (NMPA) in China has granted approval to Eli Lilly &...
Chia Tai Tianqing and China Resource Medicine Commercial Holdings Join Forces for Pharmaceutical Industry Expansion
Chia Tai Tianqing, a renowned name in the Chinese healthcare industry, has forged a strategic...
Boehringer Ingelheim’s Survodutide Earns Breakthrough Designation for MASH Treatment in China
Boehringer Ingelheim (BI), the German pharmaceutical colossus, has declared that it has been granted Breakthrough...
Innovent Biologics’ CLDN18.2-Targeted ADC IBI343 Earns FDA Fast-Track Status
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Zelgen Biopharmaceuticals’ Jacktinib Meets Primary Endpoint in Severe Alopecia Areata Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Joincare Pharmaceutical Receives NMPA Approval for Generic Seretide
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a leading pharmaceutical company based in China,...
WuXi AppTec and WuXi Bio Shares Rally as US Biosecure Act Excluded from Defense Bill
Shares of Chinese Contract Development and Manufacturing Organizations (CDMOs) WuXi AppTec (SHA: 603259) and WuXi...
Haisco Pharmaceutical’s BRAF Inhibitor HSK42360 Gains NMPA Approval for Clinical Trials
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a leading pharmaceutical company based in China, has...
Accuray Wins Chinese Nod for Precision Treatment Planning System, Boosting Regional Expansion
U.S. medical device company Accuray Inc. (NASDAQ: ARAY) has announced that it has received market...
Pfizer Forges Partnership with Flagship Pioneering for Novel Obesity Treatments
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has initiated a strategic partnership with Flagship Pioneering, a...
Eli Lilly’s Tirzepatide Hits Primary Endpoint in MASH Trial, Outperforming Placebo
Eli Lilly and Company (NYSE: LLY), a global healthcare conglomerate, has announced positive outcomes from...
AbbVie-Calico Partnership Advances with FDA Approval for Fosigotifator Trial in Rare Brain Disorder
The US Food and Drug Administration (FDA) has welcomed an experimental therapy, fosigotifator, developed by...
Junshi Biosciences’ Toripalimab Scores New Indication for First-Line ES-SCLC Treatment in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced an expansion of indications...
Kyowa Kirin’s Evocalcet Wins NMPA Nod for Chronic Kidney Disease Treatment
Kyowa Kirin Co. (TYO: 4151), a Japanese pharmaceutical firm, has secured marketing approval from China’s...
Sperogenix Launches Early Access Program for DMD Therapy Agamgree in Hainan
Switzerland-based Santhera Pharmaceuticals (SWX: SANN) has announced that its Chinese partner Sperogenix Therapeutics has initiated...
Zymeworks and BeiGene Submit BLA in China for Zanidatamab as Second-Line HER2-Positive BTC Treatment”
Zymeworks Inc. (NASDAQ: ZYME), a Canadian biotech company, in partnership with BeiGene (NASDAQ: BGNE; HKG:...
Zai Lab’s Global R&D Leadership Transition: Dr. Harald Reinhart to Retire, Dr. Rafael Amado Expands Role
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has...
FDA Committee Backs Eli Lilly’s Donanemab for Early Symptomatic Alzheimer’s Disease
This week, a US Food and Drug Administration (FDA) advisory committee endorsed the safety and...
Luye Pharma’s Paliperidone Palmitate Injection Wins NMPA Nod for Schizophrenia Treatment
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...